Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 818-820

  Toubi, E ^a,b   Kessel, A ^a   Slobodin, G ^a   Boulman, N ^a   Pavlotzky, E ^a   Zisman, D ^a   Rozenbaum, M ^a   Rosner, I ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 10; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MACROPHAGE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; UPREGULATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD86; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-10; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MACROPHAGES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249795160     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.062505     Document Type: Article

References (15)

1. Shlomchik MJ, Madaio MP, Ni D, Trounslein M, Huszar D. The role of B cells in Ipr/Ipr induced autoimmunity. J Exp Med 1994;180:1295- 306.
2. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
3. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7.
4. Edwards JC, Szczepansky L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
5. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006;176:3498-506.
6. Reinhardt RL, Hong S, Kang SJ, Wang ZE, Locksley RM. Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J Immunol 2006;177:1618-27.
7. Thein M, Phan TG, Gardam S, Amesbury C, Basten A, Mackey F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-98.
8. Pincus T, Amara I, Koch GG. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the ACR 20% criteria. Arthritis Rheum 2005;52:1031-6.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin reagent. J Biol Chem 1951;193:265-75.
10. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JCW. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment. Arthritis Rheum 2006;54:723-32.
11. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146- 54.
12. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 2005;174:3015-23.
13. Brennan FM, Foey AD, Feldmann M. The importance of T cell interactions with macrophages in rheumatoid cytokine production. Curr Top Microbiol Immunol 2006;305:177-94.
14. Scapini P, Carlelto A, Nardelli B, Calzetti F, Roschke V, Merigo F, et al. Pro-inflammatory mediators elicit the secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005;105:830-7.
15. Park HJ, Park OJ, Shin J. Receptor activator of NF-kappa ligand enhances the activity of macrophages as antigen presenting cells. Exp Mol Med 2005;37:524-32.